Abcellera Biologics Inc.

Health Care
Pharmaceuticals and Biotechnology
www.abcellera.com

Earnings Score
Moat Score

Market Cap $876.84M
PE -5
Debt $NaN
Cash $151.64M
EV $NaN
FCF -$197.36M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$175.80M
EBIT	-$202.17M
ROE	-16%
ROA	-15%
FCF	-$197.36M
Equity	$1.08B
Growth Stability	-111%
PE	-4.99
PEG	-5.85
PB	0.81
P/FCF	-4.44
P/S	26.6
Price/Cash	0.17
Net Margins	-541%
Op. Margins	-613%
Earnings CAGR	1%
Sales Growth YoY	-1%
Sales Growth QoQ	-11%
Sales CAGR	-55%
FCF CAGR	2%
Equity CAGR	90%
Earnings Stability	-0.71
Earnings Growth YoY	79%

Earnings Growth QoQ	38%
Earnings CAGR 5Y	1%
Sales CAGR 5Y	-55%
FCF CAGR 5Y	2%
Equity CAGR 5Y	90%
Earnings CAGR 3Y	-72%
Sales CAGR 3Y	-72%
FCF CAGR 3Y	-3%
Equity CAGR 3Y	-2%
Market Cap	$876.84M
Revenue	$32.96M
Assets	$1.39B
Cash	$151.64M
Shares Outstanding	290.82M
Earnings Score	6%
Moat Score	2%
Working Capital	663.32M
Current Ratio	9.34
Shares Growth 3y	1%
Equity Growth QoQ	-3%
Equity Growth YoY	-9%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

SEC Filings

Direct access to Abcellera Biologics Inc. (ABCL) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Abcellera Biologics Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Abcellera Biologics Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 1%

Stability -71%

loading chart...

Abcellera Biologics Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Abcellera Biologics Inc..

Years

Calculation mode

= -$2.3B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$197M	-$202M	-$207M	-$213M	-$218M	-$223M	-$229M	-$235M	-$240M	-$246M	-$253M	-$2.5B
DCF		-$184M	-$171M	-$160M	-$149M	-$139M	-$129M	-$120M	-$112M	-$105M	-$97M	-$974M
Value	-$2.3B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-19%	36%	41%	33%	-385%	-541%
ROA	-	16%	17%	16%	-12%	-15%
ROE	-	10%	15%	13%	-13%	-16%

Bad Net Margins (-540.92%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	0.01	-	-	-	-
Debt over Equity	-	0	-	-	-	-
Growth Stability	-	-	-	100%	-111%	-111%

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Bad Graham’s Stability (-111%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	2K%	61%	29%	-92%	-55%
Earnings YoY growth	-	-4K%	80%	3%	-192%	1%
Equity YoY growth	-	8K%	24%	20%	-7%	90%
FCF YoY growth	-	-1K%	1K%	11%	-158%	2%